A Study of Pitolisant in Participants With Prader-Willi Syndrome

Study Summary

The purpose of this study is to assess safety of pitolisant in eligible participants with Prader-Willi syndrome (PWS) who completed the End of Treatment (EOT) visit in a parent study (HBS-101-CL-002 \[Open Label Extension (OLE)\], HBS- 101-CL-004, or HBS-101-CL-312 OLE).

Conditions

Prader-Willi Syndrome

Interventions / Drugs

Pitolisant

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorHarmony Biosciences Management, Inc.

Data Retrieved2026-04-11 04:15:56.573645+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.